A unique Novo Nordisk legal challenge to the Medicare drug pricing program could have big implications for the pharma ...

Novo Nordisk argues Medicare should negotiate the price for six of its insulin products separately, though they contain the ...

Trump proposed a change to Medicare price talks that has long been sought after by the pharmaceutical industry.

Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...

When should six drugs count as one? That question is at the heart of an unusual challenge that the pharma company Novo Nordisk is pursuing against the federal government. And the answer could have ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk (NVO), which develops weight-loss ... Congress to increase the amount of time that drugs can be sold to Medicare without the government negotiating the prices to 13 years from nine ...

As CMS maintains limits on GLP-1 coverage for weight loss, new efficacy data and shifting prescribing patterns point to sustained high demand across the drug class. Here are four updates: 1. Federal ...

Novo Nordisk (NVO), which develops weight-loss drugs ... administration to work with Congress to increase the amount of time that drugs can be sold to Medicare without the government negotiating the ...